Koers VG Life Sciences Inc. Other OTC
Aandelen
VGLS
US91822T1016
Biotechnologie & Medisch Onderzoek
Omzet 2013 | - | Omzet 2014 | - | Marktkapitalisatie | 2,23 mln. 2,05 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2013 | -7 mln. -6,46 mln. | Nettowinst (verlies) 2014 | -6 mln. -5,53 mln. | EV/omzet 2013 | - |
Nettoschuld 2013 | 2,49 mln. 2,3 mln. | Nettoschuld 2014 | 3,83 mln. 3,53 mln. | EV/omzet 2014 | - |
K/w-verhouding 2013 |
-0,25
x | K/w-verhouding 2014 |
-0,31
x | Werknemers | - |
Dividendrendement 2013 * |
-
| Dividendrendement 2014 |
-
| Vrij verhandelbaar | 100% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Paul Stricklandd
BRD | Director/Board Member | 48 | 01-01-17 |
Ana Gois
IRC | Investor Relations Contact | - | - |
Corporate Officer/Principal | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Paul Stricklandd
BRD | Director/Board Member | 48 | 01-01-17 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+33,37% | 50,85 mld. | |
+1,55% | 42,82 mld. | |
+49,17% | 42,03 mld. | |
-4,22% | 29,55 mld. | |
+11,57% | 26,11 mld. | |
-21,00% | 19,13 mld. | |
+7,36% | 13,05 mld. | |
+28,30% | 12,16 mld. | |
+23,80% | 12,08 mld. |